|
WO2016118568A1
|
|
Methods and compositions for the treatment of diseases and disorders
|
|
WO2016100851A1
|
|
Methods and compositions for the treatment of retinopathy and other ocular diseases
|
|
US2017190789A1
|
|
Methods and Compositions for the Treatment of Ocular Diseases and Disorders
|
|
US2017008975A1
|
|
Anti-Tissue Inhibitor of Metalloproteinase-4 (Timp-4) Antibodies and Methods of Use Thereof
|
|
WO2013185126A2
|
|
Compositions and methods for tight junction modulation
|
|
US2013231264A1
|
|
Ultra-high throughput screening methods to detect synergistic drug interactions
|
|
EP2822593A1
|
|
Compositions and methods for treating cancer
|
|
CA2858372A1
|
|
Compositions and methods for the prevention of microbial infections
|
|
CN104114184A
|
|
Methods and compositions for the treatment of autoimmune and inflammatory diseases
|
|
EP2704799A1
|
|
Compositions and methods for the prevention of esophageal cancer
|
|
EP2430178A1
|
|
Methods and kits for measuring toxicity and oxidative stress in live cells
|
|
WO2009124252A2
|
|
Methods and compositions for the treatment of rheumatoid arthritis and other inflammatory diseases
|
|
WO2009091986A1
|
|
Use of proton pump inhibitors as drug delivery adjuvants
|
|
CN101917976A
|
|
Disulfide chemotherapeutic agents and methods of use thereof
|
|
WO2009003164A1
|
|
Compositions comprising indoleamine 2,3- dioxygenase-2 and coenzyme q inhibitors and methods of use thereof
|
|
WO2008115804A1
|
|
Novel ido inhibitors and methods of use thereof
|
|
EP2023715A2
|
|
Indoleamine-2, 3-dioxygenase-2
|
|
WO2007075672A2
|
|
Prognostic cancer markers
|
|
US2007105907A1
|
|
IDO inhibitors and methods of use thereof
|
|
EP1940787A1
|
|
Novel ido inhibitors and methods of use thereof
|
